August 24, 2022
Daiichi Sankyo said on August 23 that an application for its FLT3 inhibitor quizartinib was accepted for review by European regulatory authorities for the first-line treatment of certain patients with newly diagnosed acute myeloid leukemia (AML). The drug, known as...read more